ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

Stock Information for ADMA Biologics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ADMA Biologics Inc

ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV(TM) & BIVIGAM®
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
ADMA Biologics Announces CFO Transition
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.